We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated ce... Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Show more
Ask ADVFN Intelligence (AI)
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary...
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These...
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.16 | 8.51063829787 | 1.88 | 2.08 | 1.84 | 974104 | 1.99415165 | CS |
| 4 | 0.06 | 3.0303030303 | 1.98 | 2.15 | 1.67 | 862276 | 1.90942625 | CS |
| 12 | -1.31 | -39.1044776119 | 3.35 | 4.6 | 1.67 | 1080228 | 2.46285037 | CS |
| 26 | -1.81 | -47.012987013 | 3.85 | 5.17 | 1.67 | 798580 | 3.05444785 | CS |
| 52 | -2.77 | -57.5883575884 | 4.81 | 6.13 | 1.67 | 844348 | 3.67314567 | CS |
| 156 | -7.8 | -79.2682926829 | 9.84 | 10.98 | 1.67 | 667736 | 4.69561271 | CS |
| 260 | -9.7 | -82.6235093697 | 11.74 | 28.3 | 1.67 | 533286 | 7.97224245 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
